Using DPP-4 inhibitors to modulate beta cell function in type 1 diabetes and in the treatment of diabetic kidney disease
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Using DPP-4 inhibitors to modulate beta cell function in type 1 diabetes and in the treatment of diabetic kidney disease
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 28, Issue 4, Pages 377-388
Publisher
Informa UK Limited
Online
2019-03-08
DOI
10.1080/13543784.2019.1592156
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
- (2018) Keizo Kanasaki CLINICAL SCIENCE
- The safety of gliptins : updated data in 2018
- (2018) André Jacques Scheen Expert Opinion On Drug Safety
- Diabetic nephropathy: Is there a role for oxidative stress?
- (2018) Manpreet K. Sagoo et al. FREE RADICAL BIOLOGY AND MEDICINE
- Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials
- (2018) Giuseppe Coppolino et al. PHARMACOLOGICAL RESEARCH
- Sitagliptin inhibit human lymphocytes proliferation and Th1/Th17 differentiation in vitro
- (2017) Marcelo Maia Pinheiro et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Urinary exosomes as a novel biomarker for evaluation of α-lipoic acid's protective effect in early diabetic nephropathy
- (2017) Hanxiao Sun et al. JOURNAL OF CLINICAL LABORATORY ANALYSIS
- Dipeptidyl peptidase-4 activity is associated with urine albumin excretion in type 1 diabetes
- (2017) Lea Duvnjak et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- DPP-4 enzyme deficiency protects kidney from acute ischemia-reperfusion injury: role for remote intermittent bowel ischemia-reperfusion preconditioning
- (2017) Yen-Ta Chen et al. Oncotarget
- Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S)
- (2017) Takuya Awata et al. Diabetes Therapy
- Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S)
- (2017) Takuya Awata et al. Diabetes Therapy
- Linagliptin but not Sitagliptin inhibited transforming growth factor-β2-induced endothelial DPP-4 activity and the endothelial-mesenchymal transition
- (2016) Sen Shi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Changes of regulatory T cells, transforming growth factor-beta and interleukin-10 in patients with type 1 diabetes mellitus: A systematic review and meta-analysis
- (2016) Yong-chao Qiao et al. CLINICAL IMMUNOLOGY
- Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas
- (2016) C. F. Deacon et al. DIABETES OBESITY & METABOLISM
- Effects of linagliptin on renal endothelial function in patients with type 2 diabetes: a randomised clinical trial
- (2016) Christian Ott et al. DIABETOLOGIA
- A systematic review of the benefits and harms of dipeptidyl peptidase-4 inhibitor for chronic kidney disease
- (2016) Hiroyuki Kamiya Hemodialysis International
- Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
- (2016) Young-Sun Lee et al. MEDIATORS OF INFLAMMATION
- Impact of Immune-Modulatory Drugs on Regulatory T Cell
- (2016) Akiko Furukawa et al. TRANSPLANTATION
- Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment
- (2016) Merlin C. Thomas et al. Diabetes Therapy
- Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment
- (2016) Merlin C. Thomas et al. Diabetes Therapy
- Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA)
- (2015) R. Buzzetti et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Combination immunotherapies for type 1 diabetes mellitus
- (2015) Paolo Pozzilli et al. Nature Reviews Endocrinology
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials
- (2015) Jixin Zhong et al. Journal of Diabetes Research
- Linagliptin-Mediated DPP-4 Inhibition Ameliorates Kidney Fibrosis in Streptozotocin-Induced Diabetic Mice by Inhibiting Endothelial-to-Mesenchymal Transition in a Therapeutic Regimen
- (2014) Keizo Kanasaki et al. DIABETES
- A randomized, double-blind, placebo-controlled, phase II clinical trial to investigate the efficacy and safety of oral DA-1229 in patients with type 2 diabetes mellitus who have inadequate glycaemic control with diet and exercise
- (2014) Chang Hee Jung et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Dipeptidyl Peptidase 4 Inhibitor Sitagliptin Maintains β-Cell Function in Patients With Recent-Onset Latent Autoimmune Diabetes in Adults: One Year Prospective Study
- (2014) Yunjuan Zhao et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of GLP-1 in the Kidney
- (2014) Jeppe Skov REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
- Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial
- (2014) Kurt J Griffin et al. Lancet Diabetes & Endocrinology
- The Dipeptidyl Peptidase (DPP)-4 Inhibitors for Type 2 Diabetes Mellitus in Challenging Patient Groups
- (2013) David Kountz ADVANCES IN THERAPY
- Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease
- (2013) Jennifer B. Green et al. AMERICAN HEART JOURNAL
- Physiology and pathophysiology of incretins in the kidney
- (2013) Karoline von Websky et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- C-Peptide Levels in Latent Autoimmune Diabetes in Adults Treated With Linagliptin Versus Glimepiride: Exploratory Results From a 2-Year Double-Blind, Randomized, Controlled Study: Table 1
- (2013) Odd Erik Johansen et al. DIABETES CARE
- Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: A randomized, open label study
- (2013) K.V.S. Hari Kumar et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Pharmacokinetics and Pharmacodynamics of Linagliptin
- (2012) Ulrike Graefe-Mody et al. CLINICAL PHARMACOKINETICS
- Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney disease
- (2012) Ai-li Sun et al. Diabetes & Vascular Disease Research
- Effect of Sitagliptin on Post-Prandial Glucagon and GLP-1 Levels in Patients With Type 1 Diabetes: Investigator-Initiated, Double-Blind, Randomized, Placebo-Controlled Trial
- (2012) Satish Garg et al. Endocrine Practice
- Vildagliptin Reduces Glucagon during Hyperglycemia and Sustains Glucagon Counterregulation during Hypoglycemia in Type 1 Diabetes
- (2012) Johan Farngren et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus–Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 Study
- (2011) Benjamin M. Scirica et al. AMERICAN HEART JOURNAL
- EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE)
- (2011) William B. White et al. AMERICAN HEART JOURNAL
- Incretin Effects on -Cell Function, Replication, and Mass: The human perspective
- (2011) A. J. Garber DIABETES CARE
- Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans
- (2011) B. Ahrén et al. DIABETES OBESITY & METABOLISM
- Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial
- (2011) S. L. Ellis et al. DIABETIC MEDICINE
- Diabetic Nephropathy Amelioration by a Low-Dose Sitagliptin in an Animal Model of Type 2 Diabetes (Zucker Diabetic Fatty Rat)
- (2011) Cristina Mega et al. Experimental Diabetes Research
- Pharmacokinetics of dipeptidylpeptidase-4 inhibitors
- (2010) A. J. Scheen DIABETES OBESITY & METABOLISM
- Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
- (2010) P. L. Drury et al. DIABETOLOGIA
- Endothelial-Myofibroblast Transition Contributes to the Early Development of Diabetic Renal Interstitial Fibrosis in Streptozotocin-Induced Diabetic Mice
- (2009) Jinhua Li et al. AMERICAN JOURNAL OF PATHOLOGY
- New Definition for the Partial Remission Period in Children and Adolescents With Type 1 Diabetes
- (2009) H. B. Mortensen et al. DIABETES CARE
- Diabetic Nephropathy: Mechanisms of Renal Disease Progression
- (2008) Yashpal S. Kanwar et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats
- (2008) Yasushi Kirino et al. JOURNAL OF ENDOCRINOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search